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 Th e relationship between elevated systemic 
blood pressure (BP) and kidney disease, 
either by cause or by consequence, is immu-
 In conclusion, the study of Krishna-
murthy  et al. 1 adds to a growing body of 
evidence that dietary fi ber has important 
health-promoting properties. Dietary fi ber 
may compensate for the detrimental eff ects 
of dietary protein. Dietary fi ber and pro-
tein may thus be referred to as the yin and 
yang of Western nutrition. Rather than 
restricting the dietary protein intake, with 
inherent risks of inducing malnutrition, 
more eff orts should be taken to increase 
dietary fiber intake. Prebiotics may be 
a safe and equally effi  cacious alternative 
to increase the intake of fermentable 
carbohydrates in CKD. Health benefi ts of 
prebiotics in patients with CKD remain to 
be demonstrated by adequately designed 
and powered studies. 
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 Prehypertension and chronic 
kidney disease: the ox or the plow ? 
 John P.  Middleton 1 and  Steven D.  Crowley 1 
 Nearly ten years ago, practice recommendations supported use of the 
clinical classification of   ‘ prehypertension ’ for people with systolic blood 
pressure of 120 – 139  mm  Hg or diastolic pressure of 80 – 89  mm  Hg. 
This recommendation was based on observations that these ranges 
of blood pressure were associated with enhanced cardiovascular 
and cerebrovascular risks compared with blood pressure less than 
120 / 80  mm  Hg. Recent observations, including the report by Yano 
and colleagues, also suggest that prehypertension is an important risk 
factor for the development of chronic kidney disease. 
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table. People with BP that far exceeds aver-
age values are at risk of developing chronic 
kidney disease (CKD). The CKD that 
results from hypertension is a leading cause 
of end-stage kidney disease in the United 
States, and the ethnic predilection for 
hypertensive nephrosclerosis contributes to 
an incidence rate of end-stage kidney dis-
ease that is 3.6 times higher in African 
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Americans than in whites in the US. 1 
Moreover, for the approximately 26 million 
people in the US who are living with CKD, 
overt hypertension is a near certainty. 2 
Th e consequences of hypertension are pro-
found for patients with CKD, in whom a 
10-mm  Hg elevation of systolic pressure is 
associated with a 35 % increase in hospi-
talization for cardiovascular and cerebro-
vascular disease. 3 Decades of clinical trials 
demonstrate that if BP is controlled in 
adults with CKD, particularly with the 
use of angiotensin-converting enzyme 
inhibitors (ACEis) or angiotensin receptor 
blockers (ARBs), the medical complica-
tions of kidney disease progression can be 
substantially reduced. 4 – 6 Related observa-
tions were recently reported in children 
and adolescents. Th e Eff ect of Strict Blood 
Pressure Control and ACE Inhibition on 
Progression of Chronic Renal Failure in 
Pediatric Patients (ESCAPE) Trial demon-
strated that targeting a BP below the 50th 
percentile for age, sex, and height signifi -
cantly reduced the risk of progression of 
CKD. 7 Based on these compelling observa-
tions, the consensus practice guidelines 
endorse the use of ACEis or ARBs and 
achievement of a goal BP of   <  130 / 80  mm  Hg 
in patients who are known to have CKD. 8 
However, these proven therapies for hyper-
tension are not reaching patients who have 
CKD. For patients in the United States with 
stage 3 or 4 CKD (a glomerular fi ltration 
rate less than 60  ml / min per 1.73 m 2 ), the 
rate of adequate BP management is 
abysmal: only 24 – 58 % of patients with 
CKD are prescribed either ACEis or 
ARBs. 9,10 Moreover, only 20 % of patients 
with CKD are treated with antihyper tensive 
medications and are achieving the recom-
mended target BP of   <  130 / 80  mm  Hg. 1 As 
depicted in the scheme in  Figure 1 , eff ec-
tive delivery of proven BP therapies to 
patients in the community who are known 
to have CKD could result in health benefi ts 
to millions of people. 
 A high priority for public health, how-
ever, must also be applied to the question 
of how identifi cation of less dramatic eleva-
tions of BP foretell the development of 
CKD. Th e category of  ‘ prehypertension ’ 
was introduced in 2003 as part of the 
Seventh Report of the Joint National Com-
mittee on Prevention, Detection, Evalua-
tion, and Treatment of High Blood Pressure 
(JNC 7), and it is defined as a systolic 
pressure of 120 – 139  mm  Hg or diastolic 
pressure of 80 – 89  mm  Hg. 8 The JNC 7 
recommended that patients with prehyper-
tension be prescribed health-promoting 
lifestyle modifi cations in order to prevent 
cardiovascular disease. In part, support for 
this new classifi cation of hypertension was 
derived from studies such as the Women ’ s 
Health Initiative that associated prehyper-
tension with an increased risk of cardiovas-
cular and cerebrovascular complications, 
a risk that was not fully explained by asso-
ciated comorbidities such as diabetes, 
obesity, hyperlipidemia, and advanced 
age. 11 More recently, the potential infl u-
ence of prehypertension on the risk of 
CKD was emphasized. In a 20-year follow-
up of a health registry in Norway, the 
Health Study in Nord-Tr ø ndelag (HUNT) 
evaluated outcomes in an ethnically homo-
geneous population of more than 70,000. 12 
HUNT determined that the presence of 
prehypertension in obese people (body 
mass index     30.0  kg / m 2 ) increased the 
risk of treated end-stage kidney disease or 
CKD-related death. In the United States, a 
link was also established between prehy-
pertension and CKD in diff erent popula-
tions. In a study of more than 300,000 
people enrolled in the Kaiser health plan, 
Hsu and colleagues determined that people 
with BP in the prehypertension range had 
a 1.6- to 2-fold greater risk of developing 
end-stage kidney disease than Kaiser 
enrollees with BP less than 120 / 80  mm  Hg. 13 
In the nearly 18,000 adults surveyed in the 
National Health and Nutrition Examina-
tion Survey (NHANES) between 1999 and 
2006, the unadjusted prevalence of CKD 
among adults with prehypertension was 
13.9 % compared with 9.9 % of those sur-
veyed who had measured BP less than 
120 / 80  mm  Hg. 14 Aft er adjustment for age, 
ethnicity, and sex, the prevalence of CKD 
in prehypertensive NHANES participants 
was 17.3 % compared with 13.4 % of those 
with normal BP. Albuminuria alone (CKD 
stages 1 and 2) accounted for more than 
60 % of the cases of CKD in the NHANES 
participants who had prehypertension. 14 
Th ese cross-sectional studies implicate pre-
hypertension as an important condition for 
the genesis of CKD, but these data fail to 
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consistently establish whether the eleva-
tions in BP precede kidney disease. Fur-
thermore, these studies were not able 
to determine whether achievement of 
lower BP over time could reduce the risk 
of progressive kidney failure. 
 This compilation of observations on 
elevations of BP and the development of 
CKD is now supplemented by an interest-
ing study by Yano and colleagues 15 (this 
issue). Th ese investigators take advantage 
of a remarkable (and enviable) national 
public-health screening program in Japan. 
In this program, nearly half a million 
residents of Japan were screened for 
metabolic syndrome and hypertension. 
Yano and colleagues undertook this ana-
lysis using the nationwide data set in order 
to assess the prevalence of CKD within 
diff erent BP categories. Th e authors deter-
mine that in people with prehypertension 
with normal BP (120 – 129 / 80 – 84  mm  Hg) 
and in those with prehypertension with 
high-normal BP (130 – 139 / 85 – 89  mm  Hg), 
the prevalence of CKD was 0.7 – 1.7 and 
2 – 4.2 % higher, respectively, than in Japa-
nese men and women who had optimal 
BP. Aft er adjustment for age, cigarette use, 
and alcohol intake, the odds ratio for CKD 
risk was more consistently elevated 
in men than in women. Th e data on the 
Japanese cohort described in this paper 
exhibit similarities to the NHANES data 
in the United States, as summarized above. 
However, in the population described by 
Yano and colleagues, the majority of the 
patients classifi ed as having CKD had esti-
mated glomerular fi ltration rates below 
60  ml / min per 1.73  m 2 . Th e authors also 
describe an important interaction in their 
cohort, as the presence of obesity strength-
ened the association between CKD and 
severity of BP classifi cation, particularly 
in the males in their study. Th is is a poten-
tially important descriptive study, as the 
prevalence of advanced CKD is higher in 
Japan than in other parts of the world. 
 A few elements of the study by Yano and 
colleagues 15 deserve particular attention. 
First, the reader should note that even 
though the glomerular fi ltration rate esti-
mate was determined from serum creati-
nine concentration, the equation used in 
the study was specifi c for Asian popula-
tions and diff ers from equations such as 
the Modifi cation of Diet in Renal Disease 
(MDRD)-derived estimate. Second, the 
authors determine that those who parti-
cipated in the survey who had daily intake 
of alcohol were less likely to have demon-
strated CKD. But the nature of their data 
collection did not allow the authors 
to address this unexpected relationship 
further. Th ird, because of the nature and 
timing of the public-health program, the 
authors were not able to determine 
whether lesser degrees of hypertension 
were also associated with abject clinical 
consequences such as end-stage renal dis-
ease or cardiovascular death. Finally, the 
study design once again does not permit 
conclusions as to whether prehyper-
tension contributes to CKD or the con-
verse. Th ese results will be fascinating to 
consider in future studies, particularly 
those that address the long-term conse-
quences of prehypertension. 
 Th ese consistent relationships between 
mild elevations in BP and the prevalence 
of CKD across diverse populations sup-
port the notion that prehypertension 
renders patients susceptible to progressive 
kidney damage. On one hand, patients 
diagnosed with prehypertension may 
experience more severe and pathogenic 
elevations in BP that remain undocu-
mented in traditional clinic settings. To 
support this, clinical trials confi rm that 
BP measured in the offi  ce may not refl ect 
24-h patterns in BP variation, and that 
sustained control of 24-h ambulatory BP 
may account for the superior effi  cacy of 
ACEis in reducing target organ damage. 16 
Office measurements of BP therefore 
probably underestimate the episodes 
during which patients with prehyperten-
sion experience BP spikes that exceed the 
kidney autoregulatory threshold and thus 
permit transmission of elevated pressures 
to the renal vasculature. Beyond hemo-
dynamic consequences of BP spikes, 
the onset of CKD may also be precipitated 
by activation of local inflammatory 
cascades within the kidney. Transient 
increases in BP damage the endothelium 
within the renal vasculature and trigger 
activation of the proinfl ammatory nuclear 
factor-  B signaling pathway. 17 This 
vascular injury stimulates immune res-
ponses that lead to infi ltration of mono-
nuclear cells that propagate parenchymal 
injury in the kidney and exacerbate BP 
elevation despite the absence of a known 
putative antigen. 18 Indeed, suppression of 
immune-cell proliferation can even 
protect from the ensuing hypertension 
and associated renal injury in some 
models. 19 Th is subclinical renal injury 
leads to further elevations in BP with 
increases in dietary salt, 17 marking a 
vicious cycle in which prehypertension 
begets low-grade renal infl ammation lead-
ing to frank stage I hypertension and pro-
gressive CKD. These studies raise the 
possibility that modulating BP and / or 
immune responses in patients with pre-
hypertension might have benefi cial eff ects 
on the progression of CKD. 
 Nevertheless, it must be recognized that 
aggressive treatment for all patients with 
prehypertension would encumber extra-
ordinary resources and effort, as more 
than 30 % of the populations in the United 
States, Europe, and Japan fulfi ll this clas-
sifi cation. Th e interesting observations of 
Yano and colleagues 15 do fall short of 
determining a causal relationship between 
early elevations of BP and the onset of 
kidney disease. In addition, the authors 
accurately state that they did not address 
whether it would be cost-effective to 
screen or to treat people with prehyper-
tension in Japan. Skeptics will probably 
state that any assumption of causality 
between prehypertension and CKD will 
be placing the plow before the oxen. Th e 
preponderance of data demonstrates that 
delivery of eff ective antihypertensive thera-
pies will reduce cardiovascular, cerebro-
vascular, and kidney risks. Th erefore, these 
observations might serve as a call to action, 
bearing in mind the proverb,  ‘ the plow 
goes not well if the plowman hold it not. ’ 
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